Prothena Corporation plc

214 articles about Prothena Corporation plc

• Prothena to Participate in JMP Securities Hematology and Oncology Summit

  11/29/2021

  Prothena Corporation plc (NASDAQ:PRTA), today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday December 6, 2021 at 1:20 PM ET.

• Prothena Reports Third Quarter 2021 Financial Results and Business Highlights

  11/4/2021

  Prothena Corporation plc, a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, reported financial results for the third quarter and first nine months of 2021.

• Prothena to Report Third Quarter 2021 Financial Results on November 4th

  10/28/2021

  Prothena Corporation plc (NASDAQ:PRTA), announced today that it will report its third quarter and first nine months of 2021 financial results on Thursday, November 4, 2021 after the close of the U.S. financial markets.

• Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021

  10/1/2021

  Prothena Corporation plc, a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced that in connection with hiring two new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 140,000 ordinary shares of the Company.

• Prothena Announces Executive Appointments - Oct 01, 2021

  10/1/2021

  Prothena Corporation plc, a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced that Chief Financial Officer Tran B. Nguyen has been appointed to the additional and newly created role of Chief Strategy Officer.

• Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 03, 2021

  9/3/2021

  Prothena Corporation plc announced that in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individual hired by the Company an option to purchase 75,000 ordinary shares of the Company.

• Prothena to Participate in Upcoming September 2021 Healthcare Conferences

  9/1/2021

  Prothena Corporation plc, a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced that members of its senior management team will participate in the following September investor conferences

• Prothena Reports Second Quarter 2021 Financial Results and Business Highlights

  8/5/2021

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and first six months of 2021.

• Prothena to Report Second Quarter 2021 Financial Results on August 5th

  7/29/2021

  Prothena Corporation plc, a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced that it will report its second quarter and first six months of 2021 financial results on Thursday, August 5, 2021 after the close of the U.S. financial markets.

• Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021

  7/26/2021

  Prothena Corporation plc today announced that it presented new data at the Alzheimer’s Association International Conference® 2021 (AAIC®) from two of its Alzheimer’s disease (AD) programs.

• Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021

  7/20/2021

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that it will present preclinical data on two of its Alzheimer’s disease (AD) programs at the Alzheimer’s Association International Conference® 2021 (AAIC®),

• Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme

  7/12/2021

  Prothena Corporation plc and Novo Nordisk A/S announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme.

• 

  Novo Nordisk Takes Over Prothena's ATTR Amyloidosis Business for $1.2 Billion

  7/12/2021

  Novo Nordisk will take over Prothena's wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter's ATTR amyloidosis business and pipeline. 

• Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

  6/24/2021

  Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005;

• Prothena to Participate in JMP Securities Life Sciences Conference on June 16

  6/10/2021

  Prothena Corporation today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Wednesday, June 16 at 3:00 PM ET.

• Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors

  5/20/2021

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, MBA, to its Board of Directors.

• Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

  5/11/2021

  Net cash used in operating and investing activities was $33.7 million in the first quarter; quarter-end cash and restricted cash position of $345.7 million provides funding to advance the R&D pipeline

• Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease

  5/10/2021

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that the Company has earned a $60 million milestone from its worldwide collaboration with Roche based on the first patient dosed in the Phase 2b PADOVA study of prasinezumab in patients with early Parkinson's disease

• Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 07, 2021

  5/7/2021

  Prothena Corporation plc, a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced that in connection with hiring two new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 155,000 ordinary shares of the Company.

• Prothena to Report First Quarter 2021 Financial Results on May 11th

  5/4/2021

  Prothena Corporation plc, a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 after the close of the U.S. financial markets.